IMPORTANT NOTICE: Fraud warning for candidates. Please click the link below under "Website" or read the following before applying: https://aviadobio.com/careers/. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
| Website | http://aviadobio.com |
| Revenue | $10.7 million |
| Employees | 71 (47 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research |
| Keywords | Neurodegenerative Diseases, Biotechnology, Drug Development, Amyotrophic Lateral Sclerosis, Drug Discovery, Pharmaceutical, Als Research, Biomedical Research, Medicine Development, Precision Medicine, Clinical Trials, Therapeutic Solutions, Innovative Therapies, Disease Treatment, Rare Diseases, New Treatments, Scientific Breakthroughs, Life Sciences |
Looking for a particular AviadoBio employee's phone or email?
The AviadoBio annual revenue was $10.7 million in 2026.
Graeme Fielder is the COO of AviadoBio.
47 people are employed at AviadoBio.